Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Resverlogix Corp
ClinicalTrials.gov Identifier:
NCT00768274
First received: October 7, 2008
Last updated: July 21, 2016
Last verified: July 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: October 28, 2013